Imatinib as a paradigm of targeted therapies.
作者： Brian J. Druker
DOI: 10.1016/S0065-230X(04)91001-9
关键词:
摘要: Imatinib (Gleevec) exemplifies the successful development of a rationally designed, molecularly targeted therapy for treatment specific cancer. This article reviews identification BCR-ABL tyrosine kinase as therapeutic target in chronic myeloid leukemia and steps an agent to specifically inactivate this abnormality. The clinical trials results are reviewed along with description resistance mechanisms. As imatinib also inhibits activity KIT platelet-derived growth factor receptors, extension malignancies driven by these kinases will be described. Issues related agents discussed, including patient dose selection. Last, translation paradigm other is explored.
elsevier.com
sci-hub.se 参考文章(97)
Martin Carroll, Sayuri Ohno-Jones, Shu Tamura, Elisabeth Buchdunger, Jürg Zimmermann, Nicholas B. Lydon, D. Gary Gilliland, Brian J. Druker, CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins Blood. ,vol. 90, pp. 4947- 4952 ,(1997) , 10.1182/BLOOD.V90.12.4947.4947_4947_4952
Michael W.N. Deininger, John M. Goldman, Nicholas Lydon, Junia V. Melo, The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells Blood. ,vol. 90, pp. 3691- 3698 ,(1997) , 10.1182/BLOOD.V90.9.3691
Naomi Rosenberg, Owen N. Witte, The viral and cellular forms of the Abelson (abl) oncogene. Advances in Virus Research. ,vol. 35, pp. 39- 81 ,(1988) , 10.1016/S0065-3527(08)60708-3
Brian J. Druker, Conor Heaney, James D. Griffin, John R. Hagopian, Keiko Okuda, Tsukasa Oda, Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. Journal of Biological Chemistry. ,vol. 269, pp. 22925- 22928 ,(1994) , 10.1016/S0021-9258(17)31596-X
Brian J. Druker, Elisabeth Buchdunger, Thomas Meyer, Marcel Müller, Nicholas B. Lydon, Helmut Mett, Jürg Zimmermann, Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative Cancer Research. ,vol. 56, pp. 100- 104 ,(1996)
P. C. Nowell, A minute chromosome in human chronic granulocytic leukemia Science. ,vol. 132, pp. 1497- ,(1960)
Claudia S. Huettner, Pu Zhang, Richard A. Van Etten, Daniel G. Tenen, Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genetics. ,vol. 24, pp. 57- 60 ,(2000) , 10.1038/71691
C. G. Geary, The story of chronic myeloid leukaemia. British Journal of Haematology. ,vol. 110, pp. 2- 11 ,(2000) , 10.1046/J.1365-2141.2000.02137.X
Danny Rischin, Thierry Le Chevalier, Jason Hornick, Christopher Fletcher, Thomas Fischer, Bruce E Johnson, Sandra Silberman, Ravi Salgia, Sasa Dimitrijevic, Deanne Sayles, David Dunlop, Mildred Ortu Kowalski, Berthold Fischer, Phase II study of imatinib in patients with small cell lung cancer. Clinical Cancer Research. ,vol. 9, pp. 5880- 5887 ,(2003)
Magnus K. Magnusson, Kristin E. Meade, Ryotaro Nakamura, John Barrett, Cynthia E. Dunbar, Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene Blood. ,vol. 100, pp. 1088- 1091 ,(2002) , 10.1182/BLOOD-2002-01-0165